Subscribe
shutterstock_1492661771_ricochet64-1
ricochet64 / Shutterstock.com
25 January 2022Big PharmaMuireann Bolger

Mylan gets green light to challenge Neurim melatonin patent

Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York